KRAS and cancer: The anti-cancer activity of SB225002 has been reported in various cancers, including breast [16], ovarian [17], nasopharyngeal [18], esophageal [19], clear-cell renal cell carcinoma (CCRCC) [20], intrahepatic cholangiocellular carcinoma [21], and pancreatic cancer with activated K-Ras [22].